List of Excipients in Branded Drug AUBAGIO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genzyme Corporation	AUBAGIO	teriflunomide	58468-0211	CELLULOSE, MICROCRYSTALLINE
Genzyme Corporation	AUBAGIO	teriflunomide	58468-0211	FD&C BLUE NO. 2
Genzyme Corporation	AUBAGIO	teriflunomide	58468-0211	FERRIC OXIDE YELLOW
Genzyme Corporation	AUBAGIO	teriflunomide	58468-0211	HYDROXYPROPYL CELLULOSE
Genzyme Corporation	AUBAGIO	teriflunomide	58468-0211	HYPROMELLOSE
Genzyme Corporation	AUBAGIO	teriflunomide	58468-0211	LACTOSE MONOHYDRATE

Aubagio Excipient Strategy and Commercial Opportunities for Teriflunomide

Last updated: October 17, 2026

Aubagio is an immediate-release teriflunomide tablet marketed in 7 mg and 14 mg strengths for relapsing forms of multiple sclerosis. Its formulation uses conventional, low-cost excipients: lactose monohydrate, maize starch, hydroxypropylcellulose, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, hypromellose, talc, titanium dioxide and iron oxide colorants. The principal commercial opportunity is no longer an originator formulation franchise. It is a generic and differentiated-solid-dose opportunity built around manufacturing efficiency, excipient substitution, patient tolerability and supply reliability.

The active-ingredient product has faced generic competition in the United States following FDA approvals of teriflunomide ANDAs. Excipient strategy can support lower-cost production, lactose-free positioning, improved tablet robustness, smaller tablet size, global regulatory alignment and contract-manufacturing opportunities. It is unlikely to create a durable blocking position unless linked to a technically differentiated formulation with defensible clinical or manufacturing performance.

What is Aubagio and how is it formulated?

Aubagio contains teriflunomide, the active metabolite of leflunomide. It is supplied as film-coated tablets in two strengths:

Product	Strength	Dosage form	Typical marketed color
Aubagio	7 mg	Film-coated tablet	Light greenish-blue
Aubagio	14 mg	Film-coated tablet	Pale green to light green

The FDA-approved product is an immediate-release oral tablet. The label identifies a conventional tablet core and film-coating system rather than a modified-release, gastroretentive or multiparticulate delivery platform.[1]

The reported inactive ingredients include:

• Lactose monohydrate
• Maize starch
• Hydroxypropylcellulose
• Microcrystalline cellulose
• Sodium starch glycolate
• Magnesium stearate
• Hypromellose
• Talc
• Titanium dioxide
• Yellow iron oxide or related iron oxide colorants, depending on strength

The formulation architecture is commercially important because it relies on widely available pharmaceutical excipients and standard wet-granulation or direct-compression manufacturing capabilities. It does not require a specialized lipid system, high-barrier capsule, complex coating equipment or controlled-release polymer platform.

What excipients are used in Aubagio tablets?

The core excipients perform conventional manufacturing and performance functions.

Excipient	Primary function	Commercial implication
Lactose monohydrate	Diluent and compressibility aid	Low cost, broad supply base, but excludes lactose-free positioning
Maize starch	Binder, disintegrant and filler	Supports conventional tablet processing
Hydroxypropylcellulose	Binder	Helps granule formation and tablet strength
Microcrystalline cellulose	Filler and compression aid	Supports tablet hardness and scale-up
Sodium starch glycolate	Superdisintegrant	Promotes rapid tablet breakup
Magnesium stearate	Lubricant	Requires control of blending time and concentration
Hypromellose	Film-forming coating polymer	Standard coating excipient with broad supplier availability
Talc	Anti-tacking and coating aid	Supports coating process control
Titanium dioxide	Opacifier and color aid	Regulatory restrictions require market-specific review
Iron oxide	Colorant	Supports strength differentiation and product identification

The excipient system is not the primary source of Aubagio’s therapeutic differentiation. The active ingredient, dose, indication and established clinical profile drive product value. Excipients mainly determine manufacturability, tablet quality, patient acceptability and cost of goods.

What excipient strategy is most attractive for generic teriflunomide?

The strongest generic strategy is a Q1/Q2-equivalent formulation that preserves the reference product’s performance while simplifying procurement and manufacturing. Q1 refers to the same inactive ingredients, while Q2 refers to quantitative sameness. A generic developer can pursue a formulation that differs qualitatively or quantitatively when it meets applicable FDA requirements and demonstrates bioequivalence.

The practical priorities are:

1. Maintain rapid disintegration and dissolution.
2. Avoid excipient-driven food-effect or absorption differences.
3. Control magnesium stearate lubrication to prevent dissolution impairment.
4. Manage lactose and moisture sensitivity during granulation and storage.
5. Match tablet appearance closely enough to avoid medication errors.
6. Use a supply chain that supports both 7 mg and 14 mg strengths.
7. Preserve stability across global climatic zones.

For most applicants, the reference-like route has the lowest regulatory and development risk. A substantially different excipient system may create differentiation, but it also increases formulation-development work, analytical burden and the risk of a bioequivalence failure.

What formulation opportunities exist for Aubagio competitors?

Lactose-free teriflunomide tablets

Lactose-free tablets are the clearest patient-facing opportunity. Aubagio uses lactose monohydrate, while a competitor could replace it with combinations such as microcrystalline cellulose, mannitol, dibasic calcium phosphate or another suitable diluent.

A lactose-free product could address:

• Patients with lactose intolerance
• Institutional formularies seeking simplified excipient profiles
• Markets where lactose labeling creates procurement friction
• Patients who prefer allergen-conscious formulations

The opportunity is commercially useful but not automatically patentable. A lactose-free composition would need a technical advantage, such as improved stability, compression, dissolution or manufacturability, to support meaningful formulation IP.

Smaller tablets and improved swallowability

Teriflunomide tablets are taken once daily, which limits adherence burden. Tablet size remains relevant because patients with multiple sclerosis may have dysphagia or reduced manual dexterity.

A smaller tablet could be developed through:

• Higher-density diluents
• Optimized granulation
• Reduced coating weight
• Improved API loading
• Lower-volume superdisintegrant systems

This opportunity is more credible for patient differentiation than a basic color change. A smaller tablet can support a commercial claim only if it remains robust, bioequivalent and easy to identify.

Orally disintegrating or rapidly dispersible formulations

An orally disintegrating tablet, orally dispersible tablet or sprinkle formulation could target patients who have difficulty swallowing conventional tablets. Teriflunomide’s low daily dose makes dose loading technically feasible.

The obstacles are substantial:

• Teriflunomide taste management
• Moisture protection
• Dose uniformity
• Mechanical fragility
• Packaging requirements
• Need to demonstrate comparable exposure

Such a product would move beyond a routine ANDA strategy and may require a 505(b)(2) pathway or another regulatory approach, depending on formulation and labeling differences. The commercial case is strongest in pediatric or dysphagia-focused populations, but any new formulation would compete with inexpensive generic tablets.

Pediatric-friendly dosage forms

Aubagio is used in pediatric patients in applicable jurisdictions and age groups. A pediatric formulation could use a dispersible tablet, mini-tablet or liquid dosage form. A liquid would create additional challenges because teriflunomide has limited aqueous solubility and requires taste masking, chemical stability and preservative control.

Mini-tablets or dispersible granules may offer a more practical route than a liquid. They can reduce solvent, microbial and packaging issues while improving dose flexibility.

What manufacturing and excipient barriers affect teriflunomide?

The main manufacturing risks are conventional but material.

Lubrication control

Magnesium stearate can reduce tablet wettability when overmixed or used at excessive levels. A generic manufacturer should establish tight controls for:

• Lubricant concentration
• Lubrication time
• Blend uniformity
• Compression force
• Tablet porosity
• Dissolution profile

A formulation that appears compositionally simple can still fail comparative dissolution if lubrication is poorly controlled.

Moisture management

Starch-based systems and hypromellose coatings require moisture control during processing and storage. Excess moisture can affect tablet hardness, disintegration and stability. Low-moisture excipient grades, controlled granulation endpoints and high-barrier packaging can improve shelf-life performance.

Colorant and coating compliance

Titanium dioxide and certain colorants face different regulatory treatment across the United States, Europe and other markets. A global product may need alternate coating systems or strength-identification strategies.

Excipient supply concentration

Common excipients have multiple suppliers, but pharmaceutical-grade availability can tighten during capacity disruptions. Dual sourcing is particularly relevant for microcrystalline cellulose, lactose, hypromellose and sodium starch glycolate. A generic manufacturer with prequalified alternate suppliers can reduce launch and continuity risk.

What is the FDA regulatory status of Aubagio and generic teriflunomide?

Aubagio was approved by the FDA in 2012 for relapsing forms of multiple sclerosis. The reference product is regulated as a prescription tablet. Generic teriflunomide products are generally developed through the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[1,2]

The principal regulatory requirements include:

• Pharmaceutical equivalence
• Bioequivalence
• Equivalent strength and dosage form
• Adequate quality controls
• Stability data
• Appropriate labeling
• Compliance with current good manufacturing practice

FDA approvals of generic teriflunomide products materially changed the commercial structure of the market. The principal competitive question is now price, supply reliability, wholesaler access and formulary positioning rather than basic proof of clinical efficacy.

What is the Orange Book status and patent position for Aubagio?

The FDA Orange Book is the controlling public source for listed patents, exclusivity and approved reference-product information.[2] Aubagio’s original market protection has been overtaken by generic approvals, and teriflunomide is now exposed to generic substitution in the United States.

The relevant legal distinctions are:

Protection category	Relevance to Aubagio
Active-ingredient protection	Historical protection for teriflunomide; no longer the main commercial barrier
Formulation patents	Potentially relevant if specific composition or manufacturing claims remain enforceable
Method-of-use patents	May affect labeling or carve-out strategy if listed and unexpired
Pediatric exclusivity	Can extend qualifying listed protection, but does not independently create a long-term product moat
Regulatory exclusivity	Separate from patent term and must be checked against FDA records
ANDA litigation	Paragraph IV certifications can trigger patent litigation and a potential 30-month stay

A Paragraph IV challenge is a legal certification that a listed patent is invalid, unenforceable or not infringed. Generic applicants may also use Paragraph III certifications, wait for patent expiry, or carve out patented methods of use where permitted.

The current commercial conclusion is straightforward: an Aubagio competitor should not assume that excipient similarity creates freedom to operate. Formulation developers must review active Orange Book listings, patent family members, prosecution history, terminal disclaimers, reissue activity and applicable settlement agreements before launch.

Which companies are challenging or competing with Aubagio?

Competition comes from several groups:

• Generic manufacturers selling teriflunomide tablets
• Large generic companies with established multiple-sclerosis distribution
• Regional manufacturers in Europe, India and other regulated markets
• Specialty-pharmacy suppliers
• Developers of alternative oral and injectable disease-modifying therapies

Generic teriflunomide competes directly on price and substitution. Other multiple-sclerosis therapies compete for treatment selection and prescriber preference. These include dimethyl fumarate, diroximel fumarate, fingolimod, ozanimod, siponimod, glatiramer acetate, interferon products, natalizumab and anti-CD20 therapies.

Teriflunomide’s commercial advantages include once-daily oral administration and a simple tablet presentation. Its disadvantages include liver toxicity monitoring, teratogenicity concerns, long elimination through enterohepatic recirculation and the availability of newer high-efficacy therapies.

How strong is the Aubagio patent estate?

The commercial strength of the Aubagio estate is now moderate to weak for a conventional generic challenge. The reference product has an established formulation and regulatory history, but generic entry demonstrates that the remaining protection does not prevent market participation.

The stronger residual positions, where applicable, are likely to involve:

• Narrow formulation claims
• Specific manufacturing processes
• Crystalline or polymorphic forms
• Combination products
• Pediatric or method-of-use claims
• Jurisdiction-specific patent rights

Those positions are less likely to block a conventional immediate-release teriflunomide tablet than broad active-ingredient claims. The value of any remaining patent depends on claim scope, validity, enforceability, listed status and the ability of a generic applicant to design around it.

What commercial opportunities exist for excipient suppliers and manufacturers?

Excipient suppliers can pursue Aubagio-related opportunities in five areas.

Reference-like generic platforms

A supplier can offer a validated excipient package for immediate-release teriflunomide tablets. The value proposition is faster development, established compression behavior and reduced formulation risk.

Lactose-free systems

A prequalified lactose-free platform could support differentiated generic products and simplify allergen-related positioning.

Direct-compression systems

A co-processed filler-binder or high-functionality excipient system could reduce processing steps, improve throughput and support lower manufacturing cost.

Film-coating systems

A ready-to-use coating system can help manufacturers reproduce strength-specific appearance while adapting colorants to local regulatory requirements.

Stability and packaging solutions

Low-moisture excipients, desiccant-compatible packaging and high-barrier blister systems can support longer shelf life and international distribution.

The strongest commercial model is usually a combined package: excipient system, process parameters, analytical method support and regulatory documentation. Selling a commodity excipient alone offers less defensibility.

How does Aubagio compare with competing oral multiple-sclerosis drugs?

Product	Active ingredient	Dosage form	Excipient opportunity
Aubagio	Teriflunomide	Immediate-release tablet	Lactose-free, smaller tablet, pediatric dispersible form
Tecfidera	Dimethyl fumarate	Delayed-release capsule	Enteric coating and gastrointestinal tolerability
Gilenya	Fingolimod	Capsule	Low-dose content uniformity and capsule supply
Zeposia	Ozanimod	Capsule	Multi-strength titration and starter-pack design
Mayzent	Siponimod	Tablet	Pharmacogenetic and dose-titration packaging
Vumerity	Diroximel fumarate	Delayed-release capsule	Coating and gastrointestinal performance

Aubagio offers less formulation complexity than delayed-release fumarate products. That reduces technical barriers and development cost, but it also reduces the ability to create a differentiated excipient moat.

What generic launch scenarios exist for teriflunomide?

The most likely launch scenarios are:

1. Low-cost, reference-like tablets using standard excipients.
2. Lactose-free tablets for institutional and patient differentiation.
3. Regional products with alternate colorants or packaging.
4. Pediatric-friendly dispersible or mini-tablet products.
5. Contract-manufactured products supplied to specialty pharmacies or national generic companies.

The reference-like product will usually capture the largest volume. Differentiated products may obtain better gross margins but face narrower demand and additional regulatory costs.

Key Takeaways

• Aubagio is a 7 mg and 14 mg immediate-release teriflunomide film-coated tablet.
• Its excipient system is conventional and based on lactose, starch, microcrystalline cellulose, hydroxypropylcellulose, sodium starch glycolate and standard coating materials.
• Generic competition has shifted value away from originator exclusivity and toward cost, supply reliability and formulary access.
• Lactose-free, smaller, pediatric-friendly and dispersible formulations are the strongest excipient-led opportunities.
• A conventional excipient substitution is unlikely to create meaningful patent protection without a measurable technical advantage.
• Manufacturing controls for lubrication, moisture, dissolution and coating color are central to product quality.
• Orange Book listings, patent claims and Paragraph IV litigation must be reviewed before any commercial launch or licensing decision.
• The most defensible supplier opportunity combines excipients with process knowledge, analytical support and regulatory documentation.

Frequently Asked Questions

Can lactose be removed from an Aubagio generic?

Yes. A generic teriflunomide tablet can use a lactose-free formulation if it meets applicable pharmaceutical-equivalence, bioequivalence, quality and labeling requirements.

Is teriflunomide suitable for an orally disintegrating tablet?

Yes, from a dose-loading perspective. Taste masking, moisture control, mechanical strength and comparative bioavailability are the principal development challenges.

Are Aubagio excipients protected by patents?

Individual common excipients generally are not proprietary in this use. Patent risk may arise from a claimed composition, particle-size distribution, manufacturing process, coating system or dosage form.

Does a generic teriflunomide product need the same excipients as Aubagio?

No. The product must meet FDA requirements for pharmaceutical equivalence, bioequivalence, quality and labeling. A formulation may differ in inactive ingredients when the regulatory criteria are satisfied.

What is the highest-value excipient opportunity for teriflunomide?

A lactose-free, high-functionality immediate-release platform with validated dissolution and robust scale-up economics offers the best balance between differentiation, regulatory feasibility and commercial demand.

References

1. U.S. Food and Drug Administration. (2023). Aubagio (teriflunomide) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Product-specific guidance for teriflunomide tablets. FDA.

4. Sanofi. (2023). Annual report 2022. Sanofi.

5. European Medicines Agency. (2023). Aubagio: EPAR product information. EMA.